GeraldAlanFaichMD

PubMed

• 74 citations
  Comparative Mortality Associated With Ziprasidone and Olanzapine in Real-World Use Among 18,154 Patients With Schizophrenia: The Ziprasidone Observational Study of Car...
  Brian L. Strom, Sybil M. Eng, Gerald Faich, Robert F. Reynolds, Ralph B. D'Agostino
  The American Journal of Psychiatry. 2011-02-01
• 23 citations
  The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics.
  Brian L. Strom, Gerald Faich, Robert F. Reynolds, Sybil M. Eng, Ralph B. D'Agostino
  The Journal of Clinical Psychiatry. 2008-01-15
• 6 citations
  Lessons learned in the conduct of a global, large simple trial of treatments indicated for schizophrenia.
  Francesca Kolitsopoulos, Brian L. Strom, Gerald Faich, Sybil M. Eng, John M. Kane
  Contemporary Clinical Trials. 2013-03-01

Journal Articles

• Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research Database  
  Megan E. McAuliffea , Stephan Lanesb , Timothy Leacha , Asit Parikhc , Gerald Faichd , Jane Portera , Crystal Holickb , Daina Espositob , Yueqin Zhaob & Irving Fox, Current Medical Research and Opinion, 1/1/2015
• Comment on FDA�s quality assessment of ADE reports from an electronic health record project  
  Faich, G.A., Pharmacoepi and Drug Safety, 1/1/2012
• PV and Signaling and Disproportionality  
  Faich G, Morris J, Drug Info J, 1/1/2012
• Cardiac Event Rates in Patients with Newly Diagnosed and Relapsed Multiple Myeloma in US Clinical Practice  
  Kristin D Kistler, Kanya Rajangam, Gerald Faich and Stephan Lanes, Blood, 1/1/2012
• Comparative Mortality Associated With Ziprasidone and Olanzapine in Real-World Use Among 18,154 Patients With Schizophrenia: The Ziprasidone Observational Study of Car...  
  Brian L. Strom, Sybil M. Eng, Gerald Faich, Robert F. Reynolds, Ralph B. D'Agostino, Jeremy Ruskin, and John M. Kane, Am J Psychiatry, 1/1/2011
• Cardiac safety of diabetes therapies and postmarketing requirements  
  Faich G, Stemhagen A, Pharmacopepi and Drug Safety, 1/1/2008
• The ziprasidone observational study of cardiac outcomes (Zodiac): design and baseline subject characteristics  
  Strom BL, Faich GA, Reynolds RF, Eng SM, D'Agostino RB, Ruskin JN, Kane JM, J Clinic Psychiatry, 1/1/2008
• Incidence of allergic reactions Associated with Antibiotics  
  Johannes CB, Ziyadeh Najat, Seeger J, Tucker E, Reiter C, Faich G, Drug Safety, 1/1/2007
• Points to consider: the roles of surveillance and epidemiology in advancing drug safety  
  Edwards R, Faich G, Tilson H, Pharmicoepi and Drug Safety, 1/1/2005
• Clinical Experience with Moxifloxacin in Patients with Respiratory Tract Infections  
  Faich GA, Morganroth J, Whitehouse AB, Brar JS, Arcuri P, Kowalshy SF, Haverstock DC, Celesk, RA, Church DA, Ann Pharmacother, 1/1/2004
• Administration of parenteral iron and mortality among hemodialysis patients  
  Feldman HI, Joffe M, Robinson B, Knauss J, Cizman B, Guo W, Franklin-Becker E, Faich G, J Am Soc Nephrol, 1/1/2004
• Epidemiologic vs post-marketing spontaneous report data:vive la difference  
  Holden WL, Scarazzini L, Faich G, Pharmacoepid Drug Safety, 1/1/2004
• Cardiovascular thrombotic events in arthritis trials of the Cyclooxygenase 2 Inhibitor Celecoxib  
  White W, Faich G, Makuch R, Borer J, Am J Cardiol, 1/1/2003
• Iron administration and clinical outcomes in Hemodialysis Patients  
  Feldman H, Santanna J �.Faich G, J of Am Society of Nephrology, 1/1/2002
• Comparison of thromboembolic events in patients treated with celecoxib vs ibuprofen or diclofenac  
  White W, Faich G, Whelton A, Maurath C, Ridge N, Verberg K, Geis S, Lefkowith J, Amer J Cardiology, 1/1/2002
• Blood pressure lowering agents (letter)  
  Faich GA, Makuch R, Lancet, 1/1/2001
• Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study; a randomized controlled ...  
  Silverstein FD, Faich G, Goldstein JL, et al, JAMA, 1/1/2000
• Ferrlecit: Safer Intravenous Iron Therapy Than Iron Dextran  
  Faich GA, Strobos J, Am J of Kid Dis, 1/1/1999
• Effect of Onychomycosis On Quality of Life  
  Drake L, Scher RK, Smith EB, Faich GA, J Am Acad Derm, 1/1/1998
• Black Box Warnings In Prescription Drug Labeling: Results of a Survey of 206 Drugs  
  Beach JE, Faich GA, Sasinowski F, Food and Drug Law Journal, 1/1/1998
• Verapamil Use in Patients with Cardiovascular Disease: An Overview of Randomized Trials  
  Pepine C,Faich GA, Makuch R, Clin Cardiol, 1/1/1998
• US Adverse Drug Reaction Surveillance 1989-1994  
  Faich, G.A., Pharmacoepidem and Drug Safety, 1/1/1996
• Pharmacotherapy for Obesity-Do the Benefits Outweigh the Risks? Editorial  
  Manson J., Faich G.A., New Eng J Med, 1/1/1996
• Terfenadine - Associated Ventricular Arrhythmias A Retrospective Cohort Comparison Among Members of an HMO  
  Hanrahan, J.P., Chao, P.W., Carlson, W., Greineder, D., Faich, G.A., and Platt, R., Annals of Epidemiology, 1/1/1994
• Phase IIIB and Treatment IND Safety Reporting  
  Faich, G.A., Drug Info J, 1/1/1993
• Join now to see all

Books/Book Chapters

• Practical Risk Management 
  Chapter: Signaling and Risk Assessment 
  Faich G, Clark JEditors: Federman J, Pines WL, Slatko G.Food and Drug Law Institute2008
• Practical Risk Management 
  Chapter: Evaluation of Risk Management Programs 
  Faich G, Stemhagen AEditors: Federman J, Pines WL, Slatko G.Food and Drug Law Institute2008
• Cardiac Safety of Noncardiac Drugs:Practical Guidelines for Clinical Research and Drug Development 
  Chapter: Cardiac Arrhythmia Assessment in Phase IV Clinical Studies in Cardiac Safety of Noncardiac Drugs, Chapter 13 
  Faich G, Stemhagen AEditors: J. Morganroth and I. Gussak.Humana Press Inc., Totowa, NJ2005
• Obesity and Redux. 
  Chapter: Fenfluramines, Obesity and Primary Pulmonary Hypertension. 
  Page 99 - 104Faich, G.A.Academic Press1997
• Resource Needs for Risk Assessment in Improving Drug Safety 
  Faich, G.A.Editors: Dinkel R.Springer-Verlag, Berlin, Russia; New York, NY1991
• Clinical Trials and Tribulations 
  Chapter: Chapter 20. Postmarketing Surveillance for Drug Safety. 
  Page 347 - 361Faich, G.A., Guess, H.A., and Kuritsky, J.N.Editors: Cato A.Marcel Dekker, Inc., New York, NY1988
• The USA in Monitoring for Drug Safety. 
  Jones, J.K., Faich, G.A., and Anello, C.Editors: Inman WHW.MTP Press Ltd., Lancaster, PA; Boston, MAEdition 2nd,1986
• Simposio Sobre Disentaria Shiga en Centro America 
  Chapter: Shiga Surveillance in the US (in Spanish). 
  Faich, G.A., Lewis, J., and Gangarosa, E.J.Pan American Health Organization, WHO, Scientific Publication1974
• Textbook of Communicable and Infectious Diseases 
  Chapter: Bacterial Food Poisoning. 
  Page 259 - 266Faich, G.A. and Gangarosa, E.J.Editors: F. Top.Mosby Co, St. Louis, MO1973
• Join now to see all

Other

• Postmarketing Surveillance. Monograph. Clinical Real Life Studies Program 
  Faich, G.A.
  Clinical Medicine Research Institute, New York, NY - 1/1/1986
• Legionnaires� Disease - A Status Report 
  Faich, G.A., Association of Food and Drug Officials Quarterly Bulletin
  1/1/1979
• The Rise and Fall of Shiga Dysentery in El Salvador, 1969-1973. 
  Faich, G.A., Navarro, E.R., and Gangarosa, E.J., Bulletin of the Pan American Health Organization
  1/1/1973